Login

Journal Image
Current Radiopharmaceuticals
ISSN (Print): 1874-4710
ISSN (Online): 1874-4729
VOLUME: 6
ISSUE: 3
DOI: 10.2174/18744710113069990019      Price:  $58









Gadolinium-Deferasirox-D-Glucosamine: Novel Anti-Tumor and MR Molecular (Theranostic) Imaging Agent

img
Author(s): Massoud Amanlou, Hossein Mahian, Ahmad Molaei Rad, Seyed Ali Delbaz, Seyed Esmaeil Sadat Ebrahimi, Amir x Amir Javidi, Ali Jabbari Arabzadeh and Mehdi Shafiee Ardestani
Pages 124-136 (13)
Abstract:
Target and purpose: Cancer and heart disease are hard maladies in human communities. To recognize these kinds of diseases in primary states can help for remission and decreasing the expenses. One of the best techniques for recognizing is imaging of the tissue.

Methods: The main reason of this study is to survey the design of molecules Gd3+ - Defrasirox - DG as a type of glucose labeled with gadolinium to capture more specific cancer tissue and heart by MRI instrument as a technique extremely accurate and sensitive not too costly and lack of radioactive half-life compared with radioactive 18FDGas competing compound.

Result: In this research, glucose is combined with Deferasirox for making complexes with gadolinium. With replacing the new compound of advanced imaging technology, it transferred from nuclear medicine to Radiology and the results were evaluated in vitro and in vivo that indicated the success in imaging of the heart and cancer in animal tumor model.

Conclusion: The mechanism of cancer cells death is through activation of TNF-α system. At present, due to the lack of radiation and radioactive half-life and low production cost and high access to MRI compared with PET, this compound can be considered as 18FDG opponent in the near future as the new MRI successor agent.

Keywords:
Contrast agents, Defrasirox, cancerous tissue, MRI.
Affiliation:
The Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.